## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.95 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($217.17)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. HSBC Adjusts Price Target on IQVIA Holdings Inc to $270 From $250, Maintains Buy Rating**
- Source: MarketScreener | 20251201T104000 | Bullish | Relevance: 98%
- HSBC has increased its price target for IQVIA Holdings Inc. to $270 from $250 while reaffirming its Buy rating. This adjustment reflects a positive outlook on the company's financial performance and future prospects. The article also provides recent news and stock performance data for IQVIA Holdings Inc.

**2. IQVIA Holdings stock rating assumed at Overweight by Morgan Stanley**
- Source: Investing.com | 20251201T170500 | Bullish | Relevance: 97%
- Morgan Stanley initiated coverage on IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, suggesting a 16% upside. The firm anticipates strong demand for clinical research organization (CRO) work and highlighted IQVIA's leading position in diversified markets through its Technology & Analytics Solutions (TAS). This positive outlook is supported by recent upward revisions in earnings estimates by other analysts and the company's strong stock performance.

**3. Discipline and Rules-Based Execution in IQV Response**
- Source: Stock Traders Daily | 20251129T050200 | Neutral | Relevance: 97%
- This article from Stock Traders Daily analyzes Iqvia Holdings Inc. (NYSE: IQV), identifying strong near and mid-term sentiment, though noting elevated downside risk due to a lack of long-term support signals. It provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes a multi-timeframe signal breakdown for near, mid, and long-term outlooks for IQV.

**4. Charles River Laboratories International Inc. stock outperforms competitors on strong trading day**
- Source: MSN | 20251201T090555 | Somewhat-Bullish | Relevance: 75%
- Charles River Laboratories International Inc. (CRL) shares rose 1.83% to $201.20 on Tuesday, outperforming competitors and the broader market. Despite this daily gain, the stock has seen a significant year-to-date decline of 14.86%, contrasting with the S&P 500's 18.06% increase.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $5.8M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.95 indicates undervaluation relative to growth. Forward P/E 17.7x stretched relative to 9% growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.0B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.95 |
| Forward P/E | 17.7 |
| Current P/E | 19.2 |
| YoY Growth | 8.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.3% to 2.8% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.2pp (needs >4.0% for momentum thesis). MRS_5 (-1.2%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.9% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.66), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.82% (CS: 78) | Neutral |
| RSI_14 | 65.0 | Neutral |
| MACD Histogram | 0.66 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.088x | Above |
| vs SMA200 | 1.270x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $228.47
- **Stop Loss:** $217.17 (4.9% risk)
- **Target:** $251.07 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $15,079.02
- **Portfolio %:** 15.08%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*